Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May-Jun;54(3):208-215.
doi: 10.4103/ijp.ijp_175_21.

Hand-foot syndrome induced by chemotherapy drug: Case series study and literature review

Ahmed Zaiem  1 , Syrine Ben Hammamia  1 , Imen Aouinti  1 , Ons Charfi  1 , Walid Ladhari  2 , Sarrah Kastalli  1 , Sihem El Aidli  1 , Ghozlane Lakhoua  1
Affiliations
Review

Hand-foot syndrome induced by chemotherapy drug: Case series study and literature review

Ahmed Zaiem et al. Indian J Pharmacol. 2022 May-Jun.

Abstract

Introduction: Chemotherapy drugs can be responsible of several side effects such as hand-foot syndrome (HFS). This syndrome is also called "palmar-plantar erythrodysesthesia" and "acral erythema." Without proper management, it can deteriorate the quality of life of a patient, leading to temporary or definitive stop of chemotherapy.

Aim of this study: To identify the epidemiological and clinical characteristics of patients, the risk factors for occurrence and worsening of this syndrome, and the drugs most likely to be responsible of HFS.

Methods: Our study was retrospective, including 42 patients with HFS secondary to a chemotherapy drug. These cases were notified to the National Center of Pharmacovigilance over 7 years. The severity of HFS has been classified according to the NCI-CTCAE v4.0 classification.

Results: Our population was composed of 40 women and 2 men. The mean age was 51 years. Docetaxel was the main drug associated with this adverse effect. Hands were involved in all cases and were sometimes associated with other skin surfaces apart from feet. Erythema of the hands and/or feet was present in all patients; it was associated with edema in more than half of the cases. The distribution of different grades according to the NCI-CTCAE classification among the patients was almost equal: 28% Grade 1, 36% Grade 2, and 36% Grade 3. HFS occurred mainly after the first course of chemotherapy with a mean period of 3-4 days. The regression of HFS occurred more rapidly for Grade 1 and Grade 2 compared with Grade 3, especially when assisted by symptomatic treatment. The recurrence rate of HFS for those patients with decreased doses, spacing of cures, and/or symptomatic and prophylaxis treatment was 25%.

Conclusion: An early detection of HFS, associated with preventive measures, enables patients to continue the chemotherapy.

Keywords: Acral erythema; chemotherapy; hand–foot syndrome; palmar-plantar erythrodysesthesia; side effects.

PubMed Disclaimer

Conflict of interest statement

None

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda) Eur J Oncol Nurs. 2004;8(Suppl 1):S31–40. - PubMed
    1. Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs. 2007;11:238–46. - PubMed
    1. Nikolaou V, Syrigos K, Saif MW. Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf. 2016;15:1625–33. - PubMed
    1. Miremont-Salamé G, Théophile H, Haramburu F, Bégaud B. Causality assessment in pharmacovigilance: The French method and its successive updates. Therapie. 2016;71:179–86. - PubMed
    1. Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1:225–34. - PubMed